oxybutynin has been researched along with Metrorrhagia in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Metrorrhagia: Abnormal uterine bleeding that is not related to MENSTRUATION, usually in females without regular MENSTRUAL CYCLE. The irregular and unpredictable bleeding usually comes from a dysfunctional ENDOMETRIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mean number of bleeding/spotting episodes was comparable across groups for both reference periods, but bleeding/spotting episodes were shorter for the EE/GSD patch than the EE/NGMN patch during reference period 1 (5." | 2.80 | A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study. ( Gruber, D; Lanius, V; Merz, M; Serrani, M; Skřivánek, A, 2015) |
| "Mean number of bleeding/spotting days was comparable across treatment groups in both reference periods (p>." | 2.80 | Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. ( Bangerter, K; Kroll, R; Lynen, R; Merz, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruber, D | 1 |
| Skřivánek, A | 1 |
| Serrani, M | 1 |
| Lanius, V | 1 |
| Merz, M | 2 |
| Kroll, R | 1 |
| Lynen, R | 1 |
| Bangerter, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA[NCT00984789] | Phase 3 | 393 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and [NCT00920985] | Phase 3 | 346 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for oxybutynin and Metrorrhagia
| Article | Year |
|---|---|
A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
Topics: Adolescent; Adult; Amenorrhea; Austria; Contraceptive Agents, Female; Czech Republic; Drug Combinati | 2015 |
Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
Topics: Adolescent; Adult; Amenorrhea; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Double- | 2015 |